Healthesystems is attending the International Association of Industrial Accident Boards and Commissions Convention, which addresses policy, regulatory, and administrative challenges and opportunities affecting workers’ compensation.
Healthesystems is a proud sponsor and will be attending along with exhibiting at the American Association of State Compensation Insurance Funds conference for workers’ compensation insurance professionals.
Approval Date: Dec 2024
A biosimilar to Stelara®, this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, moderately to severely active ulcerative colitis
Approval Date: Dec 2024
An SSRI indicated for the treatment of major depressive disorder (MDD)
Approval Date: Nov 2024
A GLP-1 receptor agonist, this first-time generic is indicated for the treatment of type 2 diabetes, in conjunction with diet and exercise
Approval Date: Sep 2024
A biosimilar to Stelara, this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis
Approval Date: Aug 2024
Indicated for the treatment of opioid-induced constipation
Approval Date: Aug 2024
An opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids.
Approval Date: Aug 2024
Indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults
Approval Date: Aug 2024
Indicated for the emergency treatment of type I allergic reactions, including anaphylaxis
Approval Date: Jul 2024
Indicated for the treatment of hypertension alone or with other antihypertensive agents, and for the treatment of enlarged prostate
Approval Date: Jul 2024
Indicated for the treatment of mild to moderate dementia of the Alzheimer's type
Approval Date: Jul 2024
Indicated for the treatment of moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers
Approval Date: Jul 2024
Indicated for the treatment of Alzheimer's disease. Treatment with Kisunla should be initiated in patient with mild cognitive impairment or mild dementia stage of disease, the population in which the treatment was initiated in the clinical trials
Approval Date: Jun 2024
Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management
Approval Date: Jun 2024
Indicated for the treatment of erectile dysfunction
Approval Date: Jun 2024
A biosimilar to Stelara; indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis
